Header Logo

Connection

John Harris to Humans

Back to Details
This is a "connection" page, showing publications John Harris has written about Humans.
John Harris
Connection Strength
1.463
Humans
  1. Long TJ, Pearson TF, Harris JE. Deciphering Depigmentation: Mouse Models for Vitiligo Research. J Invest Dermatol. 2025 Sep; 145(9):2135-2146.
    View in: PubMed
    Score: 0.035
  2. Ezzedine K, Tannous R, Pearson TF, Harris JE. Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity. J Clin Invest. 2025 Jan 16; 135(2).
    View in: PubMed
    Score: 0.033
  3. Frisoli ML, Ko WC, Martinez N, Afshari K, Wang Y, Garber M, Harris JE. Single-Cell RNA Sequencing Reveals Molecular Signatures that Distinguish Allergic from Irritant Contact Dermatitis. J Invest Dermatol. 2025 May; 145(5):1117-1126.e14.
    View in: PubMed
    Score: 0.033
  4. MacDonald EA, Katz EL, Pearson TF, Harris JE. Performing Suction Blister Skin Biopsies. Curr Protoc. 2024 Jun; 4(6):e1073.
    View in: PubMed
    Score: 0.032
  5. Delva C, Pearson TF, Harris JE. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. 2024 Apr; 113(4):156-158.
    View in: PubMed
    Score: 0.032
  6. Tang Q, Fakih HH, Zain Ui Abideen M, Hildebrand SR, Afshari K, Gross KY, Sousa J, Maebius AS, Bartholdy C, S?gaard PP, Jackerott M, Hariharan V, Summers A, Fan X, Okamura K, Monopoli KR, Cooper DA, Echeverria D, Bramato B, McHugh N, Furgal RC, Dresser K, Winter SJ, Biscans A, Chuprin J, Haddadi NS, Sherman S, Yildiz-Altay ?, Rashighi M, Richmond JM, Bouix-Peter C, Blanchard C, Clauss A, Alterman JF, Khvorova A, Harris JE. Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin. Nat Commun. 2023 11 04; 14(1):7099.
    View in: PubMed
    Score: 0.031
  7. Pearson TF, Harris JE. Expanding the White Armor of Vitiligo. J Invest Dermatol. 2024 01; 144(1):5-7.
    View in: PubMed
    Score: 0.031
  8. Refat MA, Strassner JP, Frisoli ML, Rashighi M, Richmond J, Nada E, Saleh R, El-Hamd MA, Goldberg D, Mahmoud BH, Harris JE. Lesional CD8+ T-Cell Number Predicts Surgical Outcomes of Melanocyte-Keratinocyte Transplantation Surgery for Vitiligo. J Invest Dermatol. 2023 11; 143(11):2275-2282.e6.
    View in: PubMed
    Score: 0.030
  9. Vanderweil SG, Yang C, Pagani K, Chuprin J, Bernhard J, Harris JE. Assessing risk amid uncertainty inside and outside the dermatology clinic. J Am Acad Dermatol. 2023 10; 89(4):864-866.
    View in: PubMed
    Score: 0.030
  10. Paquette GM, Sherman S, Akabane A, Harris JE. Adolescent extra-truncal progressive macular hypomelanosis. Pediatr Dermatol. 2023 Jul-Aug; 40(4):702-705.
    View in: PubMed
    Score: 0.029
  11. Essien KI, Katz EL, Strassner JP, Harris JE. Regulatory T Cells Require CCR6 for Skin Migration and Local Suppression of Vitiligo. J Invest Dermatol. 2022 12; 142(12):3158-3166.e7.
    View in: PubMed
    Score: 0.028
  12. Gellatly KJ, Strassner JP, Essien K, Refat MA, Murphy RL, Coffin-Schmitt A, Pandya AG, Tovar-Garza A, Frisoli ML, Fan X, Ding X, Kim EE, Abbas Z, McDonel P, Garber M, Harris JE. scRNA-seq of human vitiligo reveals complex networks of subclinical immune activation and a role for CCR5 in Treg function. Sci Transl Med. 2021 Sep 08; 13(610):eabd8995.
    View in: PubMed
    Score: 0.026
  13. Fukuda K, Okamura K, Riding RL, Fan X, Afshari K, Haddadi NS, McCauley SM, Guney MH, Luban J, Funakoshi T, Yaguchi T, Kawakami Y, Khvorova A, Fitzgerald KA, Harris JE. AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma. J Exp Med. 2021 09 06; 218(9).
    View in: PubMed
    Score: 0.026
  14. Ko WC, Li L, Young TR, McLean-Mandell RE, Deng AC, Vanguri VK, Dresser K, Harris JE. Gene Expression Profiling in the Skin Reveals Strong Similarities between Subacute and Chronic Cutaneous Lupus that Are Distinct from Lupus Nephritis. J Invest Dermatol. 2021 12; 141(12):2808-2819.
    View in: PubMed
    Score: 0.026
  15. Rodrigues M, Pandya AG, Hamzavi I, Ezzedine K, Bekkenk MW, Harris JE. Treatment recommendations for patients with vitiligo during COVID-19. Australas J Dermatol. 2021 08; 62(3):e481-e482.
    View in: PubMed
    Score: 0.026
  16. Okamura K, Garber M, Harris JE. Gaining Insight into Vitiligo Genetics through the Lens of a Large Epidemiologic Study. J Invest Dermatol. 2021 04; 141(4):718-721.
    View in: PubMed
    Score: 0.026
  17. Katz EL, Harris JE. Translational Research in Vitiligo. Front Immunol. 2021; 12:624517.
    View in: PubMed
    Score: 0.025
  18. Rosmarin D, Butler K, Kuo F, Harris JE. Ruxolitinib cream for the treatment of vitiligo - Authors' reply. Lancet. 2020 11 28; 396(10264):1736.
    View in: PubMed
    Score: 0.025
  19. Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, Butler K, Kuo F, Sun K, Ji T, Howell MD, Harris JE. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020 07 11; 396(10244):110-120.
    View in: PubMed
    Score: 0.024
  20. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of Pathogenesis and Treatment. Annu Rev Immunol. 2020 04 26; 38:621-648.
    View in: PubMed
    Score: 0.024
  21. Riding RL, Harris JE. The Role of Memory CD8+ T Cells in Vitiligo. J Immunol. 2019 07 01; 203(1):11-19.
    View in: PubMed
    Score: 0.023
  22. Richmond JM, Strassner JP, Essien KI, Harris JE. T-cell positioning by chemokines in autoimmune skin diseases. Immunol Rev. 2019 05; 289(1):186-204.
    View in: PubMed
    Score: 0.022
  23. Tkachenko E, Refat MA, Balzano T, Maloney ME, Harris JE. Patient satisfaction and physician productivity in shared medical appointments for vitiligo. J Am Acad Dermatol. 2019 Nov; 81(5):1150-1156.
    View in: PubMed
    Score: 0.022
  24. Frisoli ML, Harris JE. Treatment with Modified Heat Shock Protein Repigments Vitiligo Lesions in Sinclair Swine. J Invest Dermatol. 2018 12; 138(12):2505-2506.
    View in: PubMed
    Score: 0.022
  25. Richmond JM, Strassner JP, Rashighi M, Agarwal P, Garg M, Essien KI, Pell LS, Harris JE. Resident Memory and Recirculating Memory T Cells Cooperate to Maintain Disease in a Mouse Model of Vitiligo. J Invest Dermatol. 2019 04; 139(4):769-778.
    View in: PubMed
    Score: 0.022
  26. Riding RL, Richmond JM, Harris JE. Mouse Model for Human Vitiligo. Curr Protoc Immunol. 2019 02; 124(1):e63.
    View in: PubMed
    Score: 0.022
  27. Richmond JM, Strassner JP, Zapata L, Garg M, Riding RL, Refat MA, Fan X, Azzolino V, Tovar-Garza A, Tsurushita N, Pandya AG, Tso JY, Harris JE. Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. Sci Transl Med. 2018 07 18; 10(450).
    View in: PubMed
    Score: 0.021
  28. Fukuda K, Harris JE. Vitiligo-like depigmentation in patients receiving programmed cell death-1 inhibitor reflects active vitiligo. J Am Acad Dermatol. 2018 01; 78(1):e15-e16.
    View in: PubMed
    Score: 0.020
  29. Kranz D, Ellison A, Mesinkovska NA, Christiano AM, Hordinsky MK, Harris JE. Building and Crossing the Translational Bridge: 2016?Alopecia Areata Research Summit Highlights. J Investig Dermatol Symp Proc. 2018 01; 19(1):S3-S8.
    View in: PubMed
    Score: 0.020
  30. Frisoli ML, Harris JE. Vitiligo: Mechanistic insights lead to novel treatments. J Allergy Clin Immunol. 2017 Sep; 140(3):654-662.
    View in: PubMed
    Score: 0.020
  31. Harris JE. Chemical-Induced Vitiligo. Dermatol Clin. 2017 Apr; 35(2):151-161.
    View in: PubMed
    Score: 0.019
  32. Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017 Apr; 35(2):257-265.
    View in: PubMed
    Score: 0.019
  33. Harris JE. Optimizing Vitiligo Management: Past, Present, and Future. Dermatol Clin. 2017 Apr; 35(2):xi.
    View in: PubMed
    Score: 0.019
  34. Strassner JP, Rashighi M, Ahmed Refat M, Richmond JM, Harris JE. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. J Am Acad Dermatol. 2017 May; 76(5):847-855.e5.
    View in: PubMed
    Score: 0.019
  35. Vanderweil SG, Amano S, Ko WC, Richmond JM, Kelley M, Senna MM, Pearson A, Chowdary S, Hartigan C, Barton B, Harris JE. A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol. 2017 Jan; 76(1):150-151.e3.
    View in: PubMed
    Score: 0.019
  36. Rashighi M, Harris JE. Sampling Serum in Patients With Vitiligo to Measure Disease Activity in the Skin. JAMA Dermatol. 2016 11 01; 152(11):1187-1188.
    View in: PubMed
    Score: 0.019
  37. Strassner JP, Harris JE. Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol. 2016 12; 43:81-88.
    View in: PubMed
    Score: 0.019
  38. Richmond JM, Bangari DS, Essien KI, Currimbhoy SD, Groom JR, Pandya AG, Youd ME, Luster AD, Harris JE. Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. J Invest Dermatol. 2017 02; 137(2):350-358.
    View in: PubMed
    Score: 0.019
  39. Rork JF, Rashighi M, Harris JE. Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr. 2016 08; 28(4):463-9.
    View in: PubMed
    Score: 0.019
  40. Rashighi M, Harris JE. Serum chemokines herald disease activity and treatment response in vitiligo patients. Br J Dermatol. 2016 Jun; 174(6):1190-1.
    View in: PubMed
    Score: 0.018
  41. Strassner JP, Rashighi M, Harris JE. Melanocytes in psoriasis: convicted culprit or bullied bystander? Pigment Cell Melanoma Res. 2016 May; 29(3):261-3.
    View in: PubMed
    Score: 0.018
  42. Harris JE. Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev. 2016 Jan; 269(1):11-25.
    View in: PubMed
    Score: 0.018
  43. Harris JE, Rashighi M, Nguyen N, Jabbari A, Ulerio G, Clynes R, Christiano AM, Mackay-Wiggan J. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016 Feb; 74(2):370-1.
    View in: PubMed
    Score: 0.018
  44. Harris JE. Melanocyte Regeneration in Vitiligo Requires WNT beneath their Wings. J Invest Dermatol. 2015 Dec; 135(12):2921-2923.
    View in: PubMed
    Score: 0.018
  45. Harris JE. IFN-? in Vitiligo, Is It the Fuel or the Fire? Acta Derm Venereol. 2015 Jul; 95(6):643-4.
    View in: PubMed
    Score: 0.017
  46. Richmond JM, Harris JE. Immunology and skin in health and disease. Cold Spring Harb Perspect Med. 2014 Dec 01; 4(12):a015339.
    View in: PubMed
    Score: 0.017
  47. Harris JE. Vitiligo and alopecia areata: apples and oranges? Exp Dermatol. 2013 Dec; 22(12):785-9.
    View in: PubMed
    Score: 0.015
  48. Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol. 2013 Dec; 25(6):676-82.
    View in: PubMed
    Score: 0.015
  49. Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-? for autoreactive CD8? T-cell accumulation in the skin. J Invest Dermatol. 2012 Jul; 132(7):1869-76.
    View in: PubMed
    Score: 0.014
  50. Patel A, Sener A, Lee SY. Reversed diastolic flow in a renal transplant due to ureteric obstruction from intraluminal blood clot. J Clin Ultrasound. 2022 May; 50(4):521-524.
    View in: PubMed
    Score: 0.013
  51. Pauli C, Kienh?fer M, G?llner S, M?ller-Tidow C. Epitranscriptomic modifications in acute myeloid leukemia: m6A and 2'-O-methylation as targets for novel therapeutic strategies. Biol Chem. 2021 Nov 25; 402(12):1531-1546.
    View in: PubMed
    Score: 0.013
  52. Harris JE, Marshak-Rothstein A. Editorial: Interfering with B cell immunity. J Leukoc Biol. 2011 Jun; 89(6):805-6.
    View in: PubMed
    Score: 0.013
  53. Harris JE, Seykora JT, Lee RA. Renbok phenomenon and contact sensitization in a patient with alopecia universalis. Arch Dermatol. 2010 Apr; 146(4):422-5.
    View in: PubMed
    Score: 0.012
  54. Harris JE, Sutton DA, Rubin A, Wickes B, De Hoog GS, Kovarik C. Exophiala spinifera as a cause of cutaneous phaeohyphomycosis: case study and review of the literature. Med Mycol. 2009 Feb; 47(1):87-93.
    View in: PubMed
    Score: 0.011
  55. Eleftheriadou V, Desai S, Bae JM, Taylor S, Meurant JM, Abdallah M, Ju HJ, Benzekri L, Wolkerstorfer A, B?hm M, Xiang LF, Rush E, Hamzavi IH, Passeron T, Lim H, Harris JE, Parsad D, Huggins R, Schneider A, Kolios A, Rosmarin D, Mohammad TF, Esmat SM, Jones J, Retzer A, Seneschal J, Gkini MA, Ahmed A, Thompson A, Pandya AG, Cruz Rivera S, Kpenou FC, Ezzedine K. Definition of Severity and Relapse for Vitiligo: An International Consensus Statement. JAMA Dermatol. 2026 May 01; 162(5):515-524.
    View in: PubMed
    Score: 0.009
  56. Wang Y, Afshari K, Haddadi NS, Lopes CS, Eng CL, Whiteman LM, Martinez N, Kyawe PP, Anufrieva KS, Wei K, Frieda K, Rosenbach M, Vleugels RA, Gallucci S, Harris JE, Rashighi M, Garber M. A spatially coordinated keratinocyte-fibroblast circuit recruits MMP9+ myeloid cells to drive type I interferon-driven inflammation in photosensitive autoimmunity. Nat Immunol. 2026 Jun; 27(6):1184-1196.
    View in: PubMed
    Score: 0.009
  57. Sherman S, Duskin-Bitan H, Agiv T, Bar D, Marom-Haham L, Levi A, Mimouni D, Chen LC, Harris JE, Levitt JB, Schonmann Y, Cohen AD, Netzer D. Bidirectional association between vitiligo and melasma: A large-scale population-based study. Indian J Dermatol Venereol Leprol. 2026 Mar-Apr; 92(2):150-156.
    View in: PubMed
    Score: 0.009
  58. Fakih HH, Zain Ui Abideen M, Rachid MO, Gross KY, Ormsby TJR, Ross VM, Gagnon R, Dahlke C, Furgal RC, Lochmann C, Summers A, Sleiman HF, F?rst SM, Jackson SN, Gordilho JO, Bouix-Peter C, Portal T, Tang Q, Harris JE, Khvorova A, Blanchard C, Alterman JF. Intradermal delivery of lipophilic siRNAs enables prolonged skin retention and sustained gene silencing in a porcine model. Nat Commun. 2026 Feb 03; 17(1).
    View in: PubMed
    Score: 0.009
  59. Gaglione SA, Mukkamala RS, Krishna C, Smith BE, Wadsworth MH, Jelinsky SA, Perez CR, Schmidt-Hong L, Katz EL, Gellatly KJ, Ali LR, Shen J, Holec PV, Zhao QH, Chan AO, Xu EJK, Kravarik KM, Guzova JA, Dobson CS, Singh H, Garber M, Dougan M, Dougan SK, Harris JE, Winkler A, Birnbaum ME. Scalable TCR synthesis and screening enable antigen reactivity mapping in vitiligo. Immunity. 2026 Feb 10; 59(2):477-493.e9.
    View in: PubMed
    Score: 0.009
  60. Seneschal J, Bae JM, Ezzedine K, Hamzavi I, Harris JE, Bellei B, Parsad D, Passeron T, van Geel N, Boniface K, Picardo M. Vitiligo. Nat Rev Dis Primers. 2025 Dec 04; 11(1):85.
    View in: PubMed
    Score: 0.009
  61. Okamura K, Arai Y, Kawaguchi J, Tsukada S, Nakamura A, Abe Y, Fukuda K, Harris JE, Suzuki T. A Hairless Mouse Model for Vitiligo: Enhancing Preclinical Therapeutic Evaluation. J Invest Dermatol. 2026 Feb; 146(2):374-382.e4.
    View in: PubMed
    Score: 0.009
  62. Ezzedine K, Parsad D, Harris JE, van Geel N, Gardner J, Bibeau K, Gao J, Ren H, Hamzavi IH. Depression and depressive symptoms among people living with vitiligo: findings from the cross-sectional, population-based global VALIANT survey. J Dermatolog Treat. 2025 Dec; 36(1):2504082.
    View in: PubMed
    Score: 0.009
  63. Tissera KA, Buros-Stein A, Delva C, Mayur O, Hawryluk EB, Harris JE, Garza-Mayers AC. Investigation of Hearing Loss in Pediatric Vitiligo. Pediatr Dermatol. 2025 Sep-Oct; 42(5):1016-1019.
    View in: PubMed
    Score: 0.008
  64. Hamzavi IH, Bibeau K, Grimes P, Harris JE, van Geel N, Parsad D, Tulpule M, Gardner J, Valle Y, Tlhong Matewa G, LaFiura C, Ren H, Ezzedine K. Exploring the natural and treatment history of vitiligo: perceptions of patients and healthcare professionals from the global VALIANT study. Br J Dermatol. 2023 10 25; 189(5):569-577.
    View in: PubMed
    Score: 0.008
  65. Bibeau K, Ezzedine K, Harris JE, van Geel N, Grimes P, Parsad D, Tulpule M, Gardner J, Valle Y, Tlhong Matewa G, LaFiura C, Lindley A, Ren H, Hamzavi IH. Mental Health and Psychosocial Quality-of-Life Burden Among Patients With Vitiligo: Findings From the Global VALIANT Study. JAMA Dermatol. 2023 10 01; 159(10):1124-1128.
    View in: PubMed
    Score: 0.008
  66. van Geel N, Speeckaert R, Ta?eb A, Ezzedine K, Lim HW, Pandya AG, Passeron T, Wolkerstorfer A, Abdallah M, Alomar A, Bae JM, Bekkenk M, Benzekri L, B?hm M, Eleftheriadou V, Esmat S, Ghia D, Goh BK, Grimes P, Gupta S, Hamzavi IH, Harris JE, Oh SH, Huggins R, Katayama I, Lan E, Lee AY, Leone G, Le Poole C, Lui H, Maquignon N, Meurant JM, Monteiro P, Oiso N, Parsad D, Pliszewski G, Raboobee N, Rodrigues M, Rosmarin D, Suzuki T, Tanemura A, Thng S, Xiang F, Zhou Y, Picardo M, Seneschal J. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the International Vitiligo Task Force Part 1: towards a new management algorithm. J Eur Acad Dermatol Venereol. 2023 Nov; 37(11):2173-2184.
    View in: PubMed
    Score: 0.008
  67. Seneschal J, Speeckaert R, Ta?eb A, Wolkerstorfer A, Passeron T, Pandya AG, Lim HW, Ezzedine K, Zhou Y, Xiang F, Thng S, Tanemura A, Suzuki T, Rosmarin D, Rodrigues M, Raboobee N, Pliszewski G, Parsad D, Oiso N, Monteiro P, Meurant JM, Maquignon N, Lui H, Le Poole C, Leone G, Lee AY, Lan E, Katayama I, Huggins R, Oh SH, Harris JE, Hamzavi IH, Gupta S, Grimes P, Goh BK, Ghia D, Esmat S, Eleftheriadou V, B?hm M, Benzekri L, Bekkenk M, Bae JM, Alomar A, Abdallah M, Picardo M, van Geel N. Worldwide expert recommendations for the diagnosis and management of vitiligo: Position statement from the international Vitiligo Task Force-Part 2: Specific treatment recommendations. J Eur Acad Dermatol Venereol. 2023 Nov; 37(11):2185-2195.
    View in: PubMed
    Score: 0.008
  68. Ren H, Akabane AL, Kelleher K, Halverstam C, Hicks M, Schachter JR, Silverman R, Chachkin S, Sherman-Bergman S, Harris JE, Kuohung V. Vitiligo induced by dupilumab treatment: A case series. J Eur Acad Dermatol Venereol. 2023 11; 37(11):2259-2261.
    View in: PubMed
    Score: 0.007
  69. Garza-Mayers AC, Paquette GM, Harris JE, Wiss K. Narrowband ultraviolet B phototherapy in pediatric vitiligo: A retrospective study. J Am Acad Dermatol. 2023 07; 89(1):135-136.
    View in: PubMed
    Score: 0.007
  70. Richmond JM, Patel D, Watanabe T, Chen HW, Martyanov V, Werner G, Garg M, Haddadi NS, Refat MA, Mahmoud BH, Wong LD, Dresser K, Deng A, Zhu JL, McAlpine W, Hosler GA, Feghali-Bostwick CA, Whitfield ML, Harris JE, Torok KS, Jacobe HT. CXCL9 Links Skin Inflammation and Fibrosis through CXCR3-Dependent Upregulation of Col1a1 in Fibroblasts. J Invest Dermatol. 2023 07; 143(7):1138-1146.e12.
    View in: PubMed
    Score: 0.007
  71. Zhou JY, Sarkar MK, Okamura K, Harris JE, Gudjonsson JE, Fitzgerald KA. Activation of the NLRP1 inflammasome in human keratinocytes by the dsDNA mimetic poly(dA:dT). Proc Natl Acad Sci U S A. 2023 01 31; 120(5):e2213777120.
    View in: PubMed
    Score: 0.007
  72. Abuabara K, Eichenfield LF, Bissonnette R, Silverberg JI, Bagel J, Guttman-Yassky E, Thaci D, Simpson EL, Harris JE, Krueger J, Myers DE, Gamelli A, Milutinovic M, Parneix A, Crawford JM, Hildebrand JS, Munoz B, Paller AS. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort. J Am Acad Dermatol. 2023 08; 89(2):345-347.
    View in: PubMed
    Score: 0.007
  73. Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Tha?i D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial. J Am Acad Dermatol. 2023 02; 88(2):395-403.
    View in: PubMed
    Score: 0.007
  74. Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 10 20; 387(16):1445-1455.
    View in: PubMed
    Score: 0.007
  75. Pandya AG, Harris JE, Lebwohl M, Hamzavi IH, Butler K, Kuo FI, Wei S, Rosmarin D. Addition of Narrow-Band UVB Phototherapy to?Ruxolitinib Cream in Patients With Vitiligo. J Invest Dermatol. 2022 12; 142(12):3352-3355.e4.
    View in: PubMed
    Score: 0.007
  76. Fatima S, Abbas T, Refat MA, Harris JE, Lim HW, Hamzavi IH, Mohammad TF. Systemic therapies in vitiligo: a review. Int J Dermatol. 2023 Mar; 62(3):279-289.
    View in: PubMed
    Score: 0.007
  77. Seneschal J, Harris JE, Le Poole IC, Passeron T, Speeckaert R, Boniface K. Editorial: Immunology of Vitiligo. Front Immunol. 2021; 12:711080.
    View in: PubMed
    Score: 0.007
  78. Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, Butler K, Kuo FI, Sun K, Grimes P. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: Descriptive subgroup analyses from a phase 2, randomized, double-blind trial. J Am Acad Dermatol. 2022 06; 86(6):1398-1401.
    View in: PubMed
    Score: 0.006
  79. Ryan GE, Harris JE, Richmond JM. Resident Memory T Cells in Autoimmune Skin Diseases. Front Immunol. 2021; 12:652191.
    View in: PubMed
    Score: 0.006
  80. Abuabara K, Silverberg JI, Simpson EL, Paller AS, Eichenfield LF, Bissonnette R, Krueger J, Harris JE, Dalfonso L, Watkins SE, Crawford JM, Tha?i D, Guttman-Yassky E. International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. BMJ Open. 2020 11 27; 10(11):e039928.
    View in: PubMed
    Score: 0.006
  81. Lyons AB, Ghia D, Abdallah M, Abdel-Malek Z, Esmat S, Ezzedine K, Grimes P, Harris JE, Lui H, Manga P, Mi QS, Pandya A, Parsad D, Passeron T, Picardo M, Seneschal J, Silpa-Archa N, Taieb A, Xiang F, Lim HW, Hamzavi IH. Proceeding Report of the Second Vitiligo International Symposium-November 9-10, 2018, Detroit, Michigan, USA. Pigment Cell Melanoma Res. 2020 07; 33(4):637-641.
    View in: PubMed
    Score: 0.006
  82. Damsky W, Patel D, Garelli CJ, Garg M, Wang A, Dresser K, Deng A, Harris JE, Richmond J, King B. Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea. J Invest Dermatol. 2020 07; 140(7):1446-1449.e4.
    View in: PubMed
    Score: 0.006
  83. van Geel N, Hamzavi I, Kohli I, Wolkerstorfer A, Lim HW, Bae JM, Lui H, Harris JE, Pandya AG, Thng Tien Guan S, Abdallah M, Esmat S, Seneschal J, Speeckaert R, Grine L, Kang HY, Raboobee N, Xiang LF, Bekkenk M, Picardo M, Taieb A. Standardizing serial photography for assessing and monitoring vitiligo: A core set of international recommendations for essential clinical and technical specifications. J Am Acad Dermatol. 2020 Dec; 83(6):1639-1646.
    View in: PubMed
    Score: 0.006
  84. van Geel N, Wolkerstorfer A, Ezzedine K, Pandya AG, Bekkenk M, Grine L, Van Belle S, Lommerts JE, Hamzavi I, Harris JE, Eleftheriadou V, Esmat S, Kang HY, Kumarasinghe P, Lan CE, Parsad D, Raboobee N, Flora Xiang L, Suzuki T, Prinsen CA, Taieb A, Picardo M, Speeckaert R. Validation of a physician global assessment tool for vitiligo extent: Results of an international vitiligo expert meeting. Pigment Cell Melanoma Res. 2019 09; 32(5):728-733.
    View in: PubMed
    Score: 0.006
  85. Mande P, Zirak B, Ko WC, Taravati K, Bride KL, Brodeur TY, Deng A, Dresser K, Jiang Z, Ettinger R, Fitzgerald KA, Rosenblum MD, Harris JE, Marshak-Rothstein A. Fas ligand promotes an inducible TLR-dependent model of cutaneous lupus-like inflammation. J Clin Invest. 2018 07 02; 128(7):2966-2978.
    View in: PubMed
    Score: 0.005
  86. Korta DZ, Christiano AM, Bergfeld W, Duvic M, Ellison A, Fu J, Harris JE, Hordinsky MK, King B, Kranz D, Mackay-Wiggan J, McMichael A, Norris DA, Price V, Shapiro J, Atanaskova Mesinkovska N. Alopecia areata is a medical disease. J Am Acad Dermatol. 2018 04; 78(4):832-834.
    View in: PubMed
    Score: 0.005
  87. Liu LY, Strassner JP, Refat MA, Harris JE, King BA. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017 Oct; 77(4):675-682.e1.
    View in: PubMed
    Score: 0.005
  88. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol. 2017 Jul; 77(1):1-13.
    View in: PubMed
    Score: 0.005
  89. Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE. Current and emerging treatments for vitiligo. J Am Acad Dermatol. 2017 Jul; 77(1):17-29.
    View in: PubMed
    Score: 0.005
  90. Mohammad TF, Al-Jamal M, Hamzavi IH, Harris JE, Leone G, Cabrera R, Lim HW, Pandya AG, Esmat SM. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol. 2017 May; 76(5):879-888.
    View in: PubMed
    Score: 0.005
  91. Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, Pandya AG. Vitiligo is not a cosmetic disease. J Am Acad Dermatol. 2015 Nov; 73(5):883-5.
    View in: PubMed
    Score: 0.004
  92. Wu S, Li WQ, Cho E, Harris JE, Speizer F, Qureshi AA. Use of permanent hair dyes and risk of vitiligo in women. Pigment Cell Melanoma Res. 2015 Nov; 28(6):744-6.
    View in: PubMed
    Score: 0.004
  93. Picardo M, Dell'Anna ML, Ezzedine K, Hamzavi I, Harris JE, Parsad D, Taieb A. Vitiligo. Nat Rev Dis Primers. 2015 06 04; 1:15011.
    View in: PubMed
    Score: 0.004
  94. Chin MS, Freniere BB, Fakhouri S, Harris JE, Lalikos JF, Crosby AJ. Cavitation rheology as a potential method for in vivo assessment of skin biomechanics. Plast Reconstr Surg. 2013 Feb; 131(2):303e-305e.
    View in: PubMed
    Score: 0.004
  95. Ram?n HE, Cejas PJ, LaRosa D, Rahman A, Harris JE, Zhang J, Hunter C, Choi Y, Turka LA. EGR-2 is not required for in vivo CD4 T cell mediated immune responses. PLoS One. 2010 Sep 23; 5(9):e12904.
    View in: PubMed
    Score: 0.003
  96. Biener L, Harris JE, Hamilton W. Impact of the Massachusetts tobacco control programme: population based trend analysis. BMJ. 2000 Aug 05; 321(7257):351-4.
    View in: PubMed
    Score: 0.002
  97. Hemavathy K, Guru SC, Harris J, Chen JD, Ip YT. Human Slug is a repressor that localizes to sites of active transcription. Mol Cell Biol. 2000 Jul; 20(14):5087-95.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.